{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-034077","form_type":"8-K","ticker":"JUNS","cik":"0001679628","company_name":"JUPITER NEUROSCIENCES, INC.","filed_at":"2026-07-21T20:05:31+00:00","discovered_at":"2026-07-21T20:07:00.466893+00:00","generated_at":"2026-07-21T20:07:29.051143+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program","bullets":["Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.","Development milestones up to $23.33M: $3.33M on Phase 3 first dosing, $20M on first FDA NDA approval.","Commercialization milestones up to $73.33M: $10M at $333M net sales, $30M at $1B, $33.33M at $2B.","Royalty of 3% on net sales in the Territory, beginning after the third commercialization milestone is payable.","Exclusive license for all human therapeutic uses in the US; Jupiter must use commercially reasonable efforts to develop and commercialize."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-034077","json":"https://secwatch.observer/filing/0001493152-26-034077.json","markdown":"https://secwatch.observer/filing/0001493152-26-034077.md","text":"https://secwatch.observer/filing/0001493152-26-034077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/0001493152-26-034077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-21T20:07:29.051143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}